![](https://cdn.sanity.io/images/0vv8moc6/oncnurse/a31ab66d75b6d2bfa02fac7474a3aff8af665ec6-1088x599.png?fit=crop&auto=format)
BNT324/DB-1311 Receives Fast Track Designation From FDA for mCRPC
Fast track designation has been granted by the FDA to the antibody-drug conjugate (ADC) BNT324/DB-1311 to potentially treat patients with unresectable advanced or metastatic castration-resistant prostate cancer (mCRPC) whose disease had progressed on …